Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.03
EGLT's Cash to Debt is ranked lower than
71% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. EGLT: 2.03 )
Ranked among companies with meaningful Cash to Debt only.
EGLT' s 10-Year Cash to Debt Range
Min: 0.91  Med: 9999.50 Max: No Debt
Current: 2.03
Equity to Asset 0.24
EGLT's Equity to Asset is ranked lower than
87% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. EGLT: 0.24 )
Ranked among companies with meaningful Equity to Asset only.
EGLT' s 10-Year Equity to Asset Range
Min: 0.24  Med: 0.76 Max: 0.85
Current: 0.24
0.24
0.85
F-Score: 2
Z-Score: -0.07
M-Score: -3.54
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -1700.20
EGLT's Operating margin (%) is ranked lower than
82% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. EGLT: -1700.20 )
Ranked among companies with meaningful Operating margin (%) only.
EGLT' s 10-Year Operating margin (%) Range
Min: -1934.17  Med: -943.77 Max: -440.97
Current: -1700.2
-1934.17
-440.97
Net-margin (%) -1785.80
EGLT's Net-margin (%) is ranked lower than
82% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. EGLT: -1785.80 )
Ranked among companies with meaningful Net-margin (%) only.
EGLT' s 10-Year Net-margin (%) Range
Min: -2250.73  Med: -1031.47 Max: -449.46
Current: -1785.8
-2250.73
-449.46
ROE (%) -120.45
EGLT's ROE (%) is ranked lower than
84% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. EGLT: -120.45 )
Ranked among companies with meaningful ROE (%) only.
EGLT' s 10-Year ROE (%) Range
Min: -444.79  Med: -444.79 Max: -444.79
Current: -120.45
ROA (%) -62.53
EGLT's ROA (%) is ranked lower than
74% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. EGLT: -62.53 )
Ranked among companies with meaningful ROA (%) only.
EGLT' s 10-Year ROA (%) Range
Min: -155.7  Med: -140.37 Max: -106.79
Current: -62.53
-155.7
-106.79
ROC (Joel Greenblatt) (%) -1359.78
EGLT's ROC (Joel Greenblatt) (%) is ranked lower than
65% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. EGLT: -1359.78 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
EGLT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1143.5  Med: -1062.19 Max: -685.58
Current: -1359.78
-1143.5
-685.58
» EGLT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

EGLT Guru Trades in

EGLT Guru Trades in

Q1 2014

EGLT Guru Trades in Q1 2014

Steven Cohen 31,594 sh (New)
» More
Q2 2015

EGLT Guru Trades in Q2 2015

Jim Simons 36,400 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with EGLT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.76
EGLT's P/B is ranked lower than
62% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. EGLT: 5.76 )
Ranked among companies with meaningful P/B only.
EGLT' s 10-Year P/B Range
Min: 1.41  Med: 3.48 Max: 9.77
Current: 5.76
1.41
9.77
P/S 59.22
EGLT's P/S is ranked lower than
82% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. EGLT: 59.22 )
Ranked among companies with meaningful P/S only.
EGLT' s 10-Year P/S Range
Min: 37.92  Med: 82.63 Max: 603
Current: 59.22
37.92
603
Current Ratio 3.87
EGLT's Current Ratio is ranked lower than
53% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. EGLT: 3.87 )
Ranked among companies with meaningful Current Ratio only.
EGLT' s 10-Year Current Ratio Range
Min: 0.86  Med: 4.78 Max: 29.19
Current: 3.87
0.86
29.19
Quick Ratio 3.74
EGLT's Quick Ratio is ranked lower than
52% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. EGLT: 3.74 )
Ranked among companies with meaningful Quick Ratio only.
EGLT' s 10-Year Quick Ratio Range
Min: 0.86  Med: 4.71 Max: 29.19
Current: 3.74
0.86
29.19
Days Inventory 1.00
EGLT's Days Inventory is ranked higher than
98% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 122.55 vs. EGLT: 1.00 )
Ranked among companies with meaningful Days Inventory only.
EGLT' s 10-Year Days Inventory Range
Min: 0  Med: 0.00 Max: 0
Current: 1
Days Sales Outstanding 182.50
EGLT's Days Sales Outstanding is ranked lower than
87% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. EGLT: 182.50 )
Ranked among companies with meaningful Days Sales Outstanding only.
EGLT' s 10-Year Days Sales Outstanding Range
Min: 56.56  Med: 107.28 Max: 321.28
Current: 182.5
56.56
321.28

Valuation & Return

vs
industry
vs
history
Price/Net Cash 19.38
EGLT's Price/Net Cash is ranked lower than
79% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. EGLT: 19.38 )
Ranked among companies with meaningful Price/Net Cash only.
EGLT' s 10-Year Price/Net Cash Range
Min: 2.15  Med: 3.63 Max: 26.24
Current: 19.38
2.15
26.24
Price/Net Current Asset Value 11.84
EGLT's Price/Net Current Asset Value is ranked lower than
69% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. EGLT: 11.84 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
EGLT' s 10-Year Price/Net Current Asset Value Range
Min: 2.09  Med: 3.80 Max: 21.92
Current: 11.84
2.09
21.92
Price/Tangible Book 9.03
EGLT's Price/Tangible Book is ranked lower than
69% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. EGLT: 9.03 )
Ranked among companies with meaningful Price/Tangible Book only.
EGLT' s 10-Year Price/Tangible Book Range
Min: 1.9  Med: 3.58 Max: 14.69
Current: 9.03
1.9
14.69
Price/Median PS Value 0.71
EGLT's Price/Median PS Value is ranked higher than
71% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. EGLT: 0.71 )
Ranked among companies with meaningful Price/Median PS Value only.
EGLT' s 10-Year Price/Median PS Value Range
Min: 0.52  Med: 1.00 Max: 5.57
Current: 0.71
0.52
5.57
Earnings Yield (Greenblatt) (%) -23.00
EGLT's Earnings Yield (Greenblatt) (%) is ranked lower than
80% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. EGLT: -23.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
EGLT' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -44.3  Med: 0.00 Max: 0
Current: -23
-44.3
0

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 7 42 150
EPS($) -3.58 -2.03 0.12
EPS without NRI($) -3.58 -2.03 0.12

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
» More Articles for EGLT

Headlines

Articles On GuruFocus.com
Wall Street’s Best and Worst Calls of the First Quarter 2015 May 07 2015 

More From Other Websites
Edited Transcript of EGLT earnings conference call or presentation 6-Aug-15 12:00pm GMT Aug 27 2015
EGALET CORP Financials Aug 19 2015
New Strong Buy Stocks for August 12th Aug 12 2015
EGALET CORP Files SEC form 10-Q, Quarterly Report Aug 07 2015
Q2 2015 Egalet Corp Earnings Release - Time Not Supplied Aug 06 2015
EGALET CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 06 2015
Egalet reports 2Q loss Aug 06 2015
Egalet reports 2Q loss Aug 06 2015
Egalet Reports Second Quarter 2015 Financial Results and Provides Business Update Aug 06 2015
EGALET CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 31 2015
Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters'... Jul 31 2015
EGALET CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial... Jul 28 2015
Main Line pain drugmaker plans $75M stock sale Jul 28 2015
Egalet Announces Pricing of Public Offering of Common Stock Jul 28 2015
Egalet Announces Proposed Public Offering of Common Stock Jul 27 2015
Egalet to Host Conference Call and Webcast to Discuss Second Quarter 2015 Financial Results on... Jul 23 2015
EGALET CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jul 08 2015
EGALET CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... Jul 02 2015
Egalet Reports Encouraging Results on Pain Drug Egalet-002 - Analyst Blog Jul 01 2015
EGALET CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 01 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK